Alzheimer's Disease

A phase 1/phase 2 study will evaluate the efficacy and safety of azeliragon for patients refractory to first-line treatment for metastatic pancreatic cancer.

A South Korea-based life sciences company has announced expansion into the European Union, United Kingdom, Korea and China of its phase 3 study of an oral, investigational PDE5 inhibitor to treat early Alzheimer’s disease.

RetinalGeniX Technologies announced that it submitted patent applications for investigational drug candidates RTG-2023 and RTG-2024, for age-related macular degeneration and Alzheimer’s, respectively.

A Canadian neuroimaging company has received an investment from the Alzheimer’s Drug Discovery Foundation to accelerate development of novel biomarkers for Alzheimer’s disease and related dementias.

Annovis Bio has been permitted by the Data and Safety Monitoring Board to continue its phase 2/3 trial of buntanetap, an oral protein inhibitor for moderate to mild Alzheimer’s disease, according to a company release.

In a cohort of older adults, the COVID-19 pandemic was a mitigating factor in self-perceived cognitive decline, the presence of which indicated a higher risk factor for worsening cognitive function in the year following the pandemic.

For early detection of Alzheimer’s disease in older adults, comorbidities remained strongly associated with mild cognitive impairment, but prediction decreased with age, according to a poster presentation at CTAD.

An artificial intelligence-based machine learning model that diagnosed cognitive impairment in Alzheimer’s disease extracted information more accurately than standard screening or human analysis, according to a poster presentation at CTAD.

Mounting evidence suggests that herpes simplex virus 1 may be associated with an increased risk for Alzheimer’s disease and dementia, according to a systematic review of published studies.

For clinicians who treat patients with Alzheimer’s disease, quantification of amyloid positron emission tomography was feasible and possessed a high degree of concordance with visual analysis, according to a presentation at CTAD.